NCT03375697View on ClinicalTrials.gov

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 22, 2017

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions

Alzheimer Disease

Interventions

DRUG

JNJ-63733657

Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.

DRUG

Placebo

Subjects will receive matching placebo intravenously.

Trial Locations (7)

2170

Clinical Pharmacology Unit, Merksem

20251

CTC North GmbH & Co. KG, Hamburg

28040

Hosp. Clinico San Carlos, Madrid

46026

Hosp. Univ. I Politecni La Fe, Valencia

53127

Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Bonn

66421

Universitätsklinikum des Saarlandes, Homburg / Saar

2333 CL

Centre for Human Drug Research, Leiden

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03375697 - A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease | Biotech Hunter | Biotech Hunter